Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat ...

REX-8756 is a potent and selective oral STAT6 inhibitor that has shown complete 100% pathway inhibition and potent efficacy in preclinical models of asthma, acute lung inflammation and ...

The U.S. Food and Drug Administration approved on Tuesday the first drug under its new fast-track program designed to shorten ...

An announcement from Praxis Precision Medicines ( ($PRAX) ) is now available. On December 9, 2025, Praxis Precision Medicines announced the ...

Representatives of companies including AbbVie, Eli Lilly, Johnson & Johnson and Merck have voiced concerns about the FDA’s ...

Olanzapine long-acting injectable (LAI) has the potential to offer the efficacy of olanzapine in a once-monthly, subcutaneous formulation, for a ...

Wockhardt's shares jumped 19.3% to ₹1,473 following the US FDA's acceptance of its antibiotic drug Zaynich's New Drug Application. The pharma shares have remained under pressure since hitting a ...

Disc Medicine Inc. (NASDAQ: IRON) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, ...

If approved, CUTX-101 will be the first and only FDA-approved treatment available for Menkes disease, a rare X-linked ...

We found that one-third of pharmaceutical companies proactively released the launch price of their medications between 2022 and 2024, and another third released them reactively. Smaller public ...

Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that Ascletis ...

Abivax receives a "Strong Buy" rating, driven by positive phase 3 ABTECT induction data for obefazimod in moderate-to-severe ...